PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
CMB International Global Markets  Equity Research  Company Update
WuXi AppTec (603259 CH)
Healthy growth amid challenging environment
Healthy earnings growth in 1Q23 WuXi AppTec reported 1Q23 revenue of
accounted for 21% 22% of our 2023 full-year estimates which were also in line
with its historical range Non-IFRS gross profit margin (GPM) improved by 32ppt
to 410% while non-IFRS net profit margin increased by 19ppt to 261% in 1Q23
driven by the continuously improved operating efficiency and output per
employee Non-COVID business saw resilient growth in 1Q23 with DM revenue
(in WuXi Chemistry segment) up 30% YoY Given the high revenue base of 2022
management reiterated 5-7% YoY and 12-14% YoY growth target for its revenue
and non-IFRS gross profit respectively in 2023E
 Global healthcare funding slow-down remains a key factor to be
watched According to VBDATA global China healthcare funding decreased
by 41% 57% YoY in 1Q23 following the decline of 43% 54% YoY in 2022
We believe top CXO players such as WuXi AppTec will be less impacted by
the demand cycle thanks to its superior client mix and strong bargaining
power to clients In fact WuXi AppTecs 1Q23 revenue from biotech clients
surged by 53% YoY with over 310 new clients added in the quarter
 New modalities services turning into new growth drivers Revenue of
new modalities-related services in WuXi Chemistry segment grew by 44%
YoY to RMB540mn in 1Q23 representing 96% (vs 104% in 2022) of
modalities revenue of WuXi Biology segment delivered a 40% YoY growth in
1Q23 representing 253% (vs 225% in 2022) of segment revenue The
Company has built the largest drug discovery team in the world functioning
as a critical project source for its downstream services More synergies
among its various business segments are yet to be released
 WuXi ATU and DDSU saw encouraging progress despite business
adjustments Pipeline of WuXi ATU included eight projects in Ph3 as of
1Q23 with two in BLA review stage and another two in BLA preparation
anticipated BLA approvals With the adjustment of Lingang site management
indicated GPM of WuXi ATU to turn positive for full-year 2023E Additionally
a customer of DDSU segment obtained marketing approval for a new COVID
 Maintain BUY We cut TP from RMB12152 to RMB 11069 based on a 10-
year DCF model with WACC of 1157% and terminal growth of 30% to reflect
uncertainties in healthcare funding We forecast WuXi AppTecs revenue to
by 93% 274% 244% YoY in 2023E 24E 25E respectively
(Previous TP
RMB12152)
UpDownside
Jill WU CFA
Benchen HUANG CFA
Mkt Cap (RMB mn)
Avg 3 mths to (RMB mn)
52w HighLow (RMB)
Total Issued Shares (mn)
Source FactSet
Shareholding Structure
Ge Li and concerted parties
Source Company
Source FactSet
12-mth Price Performance
Source FactSet
(YE 31 Dec)
Revenue (RMB mn)
YoY growth (%)
Adjusted net profit (RMB mn)
EPS (Adjusted) (RMB)
Consensus EPS (RMB)
PE (x) (adjusted)
Source Company data Bloomberg CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 1 Earnings revision
Non-IFRS net profit
Non-IFRS EPS (RMB)
Source Company data CMBIGM estimates
Figure 2 CMBIGM estimates vs consensus
Non-IFRS net profit
Non-IFRS EPS (RMB)
Source Company data Bloomberg CMBIGM estimates
Figure 3 Valuation on risk-adjusted DCF valuation
DCF Valuation (in Rmb mn)
EBIT(1-tax rate)
- Change in working capital
Target Debt to Asset ratio
Effective Corporate Tax Rate
PV of terminal value (RMB mn)
Total PV (RMB mn)
Net debt (RMB mn)
Equity value (RMB mn)
 of shares (mn)
Price per share (RMB per share)
Source CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
RD expense
Gainloss on financial assets at FVTPL
Investment gainloss
Pre-tax profit
YE 31 Dec (RMB mn)
Cash  equivalents
Financial assets at FVTPL
Non-current assets
Investment in JVs  assos
Financial assets at FVTPL
Other non-current assets
Short-term borrowings
Other current liabilities
Non-current liabilities
Long-term borrowings
Obligations under finance leases
Other non-current liabilities
Total shareholders equity
Total equity and liabilities
YE 31 Dec (RMB mn)
Profit before taxation
Depreciation  amortization
Change in working capital
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Net cash from operations
Acquisition of subsidiaries investments
Net proceeds from disposal of short-term
Net cash from investing
Proceeds from share issues
Net cash from financing
Cash at the beginning of the year
Cash at the end of the year
Adj net profit
Adj net profit margin
Return on equity (ROE)
GEARINGLIQUIDITYACTIVITIES
Net debt to equity (x)
Current ratio (x)
Receivable turnover days
Inventory turnover days
Payable turnover days
PE (adjusted)
Div yield (%)
Note The calculation of net cash includes financial assets  Source Company data CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities
or issuer that the analyst covered in this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities
this report
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities
and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue
of this report (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report (3) serve as
covered in this report
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIGM
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Global Markets Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Global Markets Limited (CMBIGM) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned
subsidiary of China Merchants Bank)
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors  CMBIGM
does not provide individually tailored investment advice This report has been prepared without regard to the individual investment objectives financial position
or special requirements  Past performance has no indication of future performance and actual events may differ materially from that which is contained in the
report  The value of and returns from any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the
and strategies and encourages investors to consult with a professional financial advisor in order to make their own investment decisions
This report or any information contained herein have been prepared by the CMBIGM solely for the purpose of supplying information to the clients of CMBIGM
or its affiliate(s) to whom it is distributed  This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in
securities or enter into any transaction  Neither CMBIGM nor any of its affiliates shareholders agents consultants directors officers or employees shall be
liable for any loss damage or expense whatsoever whether direct or consequential incurred in relying on the information contained in this report  Anyone
making use of the information contained in this report does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable
the information advices and forecasts on an AS IS basis  The information and contents are subject to change without notic e CMBIGM may issue other
publications having information and or conclusions different from this report  These publications reflect different assumption point-of-view and analytical
this report
on behalf of its clients from time to time Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with
and CMBIS will not assume any responsibility in respect thereof This report is for the use of intended recipients only and this publication may not be reproduced
reprinted sold redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended from time to time)(The Order) or (II) are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies Unincorporated Associations
etc) of the Order and may not be provided to any other person without the prior written consent of CMBIGM
For recipients of this document in the United States
CMBIGM is not a registered broker-dealer in the United States  As a result CMBIGM is not subject to US rules regarding the preparation of research reports
and the independence of research analysts  The research analyst who is primary responsible for the content of this research report is not registered or qualified
as a research analyst with the Financial Industry Regulatory Authority (FINRA)  The analyst is not subject to applicable restrictions under FINRA Rules
intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report This report is
intended for distribution in the United States solely to major US institutional investors as defined in Rule 15a-6 under the US Securities Exchange Act of
1934 as amended and may not be furnished to any other person in the United States Each major US institutional investor that receives a copy of this report
by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person Any US recipient of this report wishing to
effect any transaction to buy or sell securities based on the information provided in this report should do so only through a US-registered broker-dealer
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser as defined
in the Financial Advisers Act (Cap 110) of Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute reports produced by its
respective foreign entities affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations
Where the report is distributed in Singapore to a person who is not an Accredited Investor Expert Investor or an Institutional Investor as defined in the Securities
and Futures Act (Cap 289) of Singapore CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law
Singapore recipients should contact CMBISG at 65 6350 4400 for matters arising from or in connection with the report